ePrints

Hurdles in therapy with regulatory T cells

Lookup NU author(s): Professor Catharien Hilkens

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Improper activation of the immune system contributes to a variety of clinical conditions, including autoimmune and allergic diseases as well as solid organ and bone marrow transplantation. One approach to counteract this activation is through adoptive therapy with regulatory T cells (T-regs). Efforts to manufacture these cells have led to good maunfacturing practice-compliant protocols, and T-reg products are entering early clinical trials. Here, we report the stance of the European Union Cooperation in Science and Technology Action BM1305, "Action to Focus and Accelerate Cell-based Tolerance-inducing Therapies-A FACTT," which identifies hurdles hindering T-reg clinical applications in Europe and provides possible solutions.

Publication metadata

Author(s): Trzonkowski P, Bacchetta R, Battaglia M, Berglund D, Bohnenkamp HR, ten Brinke A, Bushell A, Cools N, Geissler EK, Gregori S, van Ham SM, Hilkens C, Hutchinson JA, Lombardi G, Madrigal JA, Marek-Trzonkowska N, Martinez-Caceres EM, Roncarolo MG, Sanchez-Ramon S, Saudemont A, Sawitzki B

Publication type: Article

Publication status: Published

Journal: Science Translational Medicine

Year: 2015

Volume: 7

Issue: 304

Print publication date: 09/09/2015

Acceptance date: 01/01/1900

ISSN (print): 1946-6234

ISSN (electronic): 1946-6242

Publisher: American Association for the Advancement of Science

URL: http://dx.doi.org/10.1126/scitranslmed.aaa7721

DOI: 10.1126/scitranslmed.aaa7721

Altmetrics

Funding

Share